Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer-Reference-Cited by-同舟云学术

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

Published:2020-02 Issue:2 Volume:77 Page:269-276
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Gómez de Liaño Lista Alfonso,van Dijk Nick,de Velasco Oria de Rueda Guillermo,Necchi Andrea^ORCID,Lavaud Pernelle,Morales-Barrera Rafael,Alonso Gordoa Teresa,Maroto Pablo,Ravaud Alain,Durán Ignacio^ORCID,Szabados Bernadett,Castellano Daniel,Giannatempo Patrizia,Loriot Yohann,Carles Joan,Anguera Palacios Georgia,Lefort Felix,Raggi Daniele,Gross Goupil Marine,Powles Thomas,Van der Heijden Michiel S.

Publisher

Elsevier BV

Subject

Urology

Reference29 articles.

1. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;Powles;Nature,2014

2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;Rosenberg;Lancet,2016

3. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017

4. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial;Powles;Lancet,2018

5. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial;Sharma;Lancet Oncol,2017

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1;International Immunopharmacology;2024-12

2. Palliative Systemtherapie des metastasierten Urothelkarzinoms der Harnblase;TumorDiagnostik & Therapie;2024-03

3. The Expression and Prognostic Significance of P3H1 in Bladder Cancer: A Bioinformatics Analysis and In Vitro Experiments;2024-01-22

4. Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era;Clinical Genitourinary Cancer;2023-12

5. Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma;Frontiers in Pharmacology;2023-11-13